ASH 2022: Updated Index Improves Prognostication for Survival in Advanced-Stage Hodgkin Lymphoma Models that have historically been used to predict survival outcomes in advanced-stage classical Hodgkin lymphoma (A-HL) are outdated and less useful in the modern treatment era. Members of…
ASH 2022: Next-Generation BTKi Zanubrutinib Demonstrates Improved Efficacy and Tolerability Compared with Ibrutinib The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib (Imbruvica) has become the standard treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) but can cause…
ASH 2022: Durable Responses Observed with Mosunetuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma In research presented by Nancy Bartlett, MD, a past Scientific Advisory Board (SAB) member and LRF grantee, durable clinical responses were observed in patients with relapsed/refractory follicular lymphoma…
ASH 2022: Quality of Life Improves Quickly in Survivors of Aggressive Lymphomas Lymphomas are a potentially curable subset of cancers, but long-term treatment or disease effects may impact quality of life. Researchers, therefore, sought to determine how quality of life…
ASH 2022: Short-course Brentuximab Vedotin with Chemotherapy is Highly Active in Early-Stage Bulky Hodgkin LymphomaASH 2022 Treatment with short-course brentuximab vedotin (Adcetris; BV), an antibody-drug conjugate, combined with chemotherapy in early-stage, bulky Hodgkin lymphoma (HL) was associated with four-year overall…
Where Are They Now? Deborah Stephens, DO When did you become interested in the study of medicine? In lymphoma specifically? I grew up on a farm, and my mom told me she knew I would go into medicine because I…
A Multi-Layered View to Lymphoma Research Some people are born to be scientists, and Eric D. Hsi, MD, Department Chair of Pathology at Wake Forest University School of Medicine, is one such person. While he may have always known he…
On January 27, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved pirtobrutinib (Jaypirca, Eli Lilly and Company), for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.…
On January 19, the U.S. Food and Drug Administration (FDA) announced it has approved bruton tyrosine kinase (BTK), zanubrutinib (Brukinsa, BeiGene), for chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL). BTK is a protein critical for the growth and survival of B-cells. BTK…
On December 22, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific antibody, for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) after two or more…